{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"17.340","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"672,361,350","primaryexch":"香港交易所","ric":"2256.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0446,"inline_upper_strike_price":"","sedol":"BMCP6L9","am":"82.17","iv":"","ew_strike":"","as":"16.950","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"16.880","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"3.120","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"徐耀昌","underlying_ric":"2256.HK","hi52":"18.920","issuer_name":"和譽開曼有限責任公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"16.510","mkt_cap":"11.39","f_aum_hkd":null,"ew_sub_per_to":"","ls":"16.950","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.280","aum":"","issued_shares_class_B":null,"vo":"4.83","secondary_listing_flag":false,"listing_date":"2021年10月13日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"和譽開曼有限責任公司 - B","nm_s":"和譽－Ｂ","sym":"2256","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"和譽開曼有限責任公司是一家臨牀階段生物製藥公司。該公司致力於發現和開發創新差異化的小分子腫瘤療法。該公司擁有兩款核心候選產品ABSK011和 ABSK091，以及12款其他在研產品。ABSK011是一種強效且高選擇性的成纖維細胞生長因子受體4(FGFR4) 小分子抑制劑。ABSK091 是一種分子靶向候選產品，也是 FGFR亞型 1、2和3的強效和選擇性抑制劑。該公司的產品主要用於肝細胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","op":"17.300","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40樓","pc":"-1.63","days_to_expiry":null,"underlying_code":null,"pe":"359.87","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"17.230","isin":"KYG0028A1085","moneyness":""}},"qid":"1759074173341"}
